What’s New in aHUS Research: Summer 2025
The aHUS Alliance Global Action team remains strong advocates for those affected by the rare disease atypical HUS, and proudly partners…
aHUS Drug Candidates – the 2022 Landscape
What’s new in 2022 regarding expansion in atypical HUS knowledge, and advancements for investigational drugs which may have potential as new…
Small Molecule Factor D Inhibitors – Right for aHUS?
Out of more than 7000 rare diseases, only an estimated 5% have an approved treatment or therapy (Rare Disease Day, FAQs).…
Generium’s Elizaria: First Biosimilar to Eculizumab
Generium launches the first biosimilar drug to eculizumab, known as Elizaria. What is a biosimilar? What might this biosimilar mean for aHUS patients, and the physicians who treat them? The aHUS Alliance looks at the science behind biosimilars, as well as issues such as drug cost and access for those affected by the rare disease atypical HUS.